Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

Opposing roles for membrane bound and soluble Fas ligand in glaucoma-associated retinal ganglion cell death.

Meredith S Gregory | Caroline G Hackett | Emma F Abernathy | Karen S Lee | Rebecca R Saff | Andreas M Hohlbaum | Krishna-Sulayman L Moody | Maura W Hobson | Alexander Jones | Paraskevi Kolovou | Saoussen Karray | Andrea Giani | Simon W M John | Dong Feng Chen | Ann Marshak-Rothstein | Bruce R Ksander
PloS one | 2011

Glaucoma, the most frequent optic neuropathy, is a leading cause of blindness worldwide. Death of retinal ganglion cells (RGCs) occurs in all forms of glaucoma and accounts for the loss of vision, however the molecular mechanisms that cause RGC loss remain unclear. The pro-apoptotic molecule, Fas ligand, is a transmembrane protein that can be cleaved from the cell surface by metalloproteinases to release a soluble protein with antagonistic activity. Previous studies documented that constitutive ocular expression of FasL maintained immune privilege and prevented neoangeogenesis. We now show that FasL also plays a major role in retinal neurotoxicity. Importantly, in both TNFα triggered RGC death and a spontaneous model of glaucoma, gene-targeted mice that express only full-length FasL exhibit accelerated RGC death. By contrast, FasL-deficiency, or administration of soluble FasL, protected RGCs from cell death. These data identify membrane-bound FasL as a critical effector molecule and potential therapeutic target in glaucoma.

Pubmed ID: 21479271

Research resources used in this publication

None found

Additional research tools detected in this publication

Antibodies used in this publication

None found

Associated grants

  • Agency: NEI NIH HHS, United States
    Id: R01 EY016486
  • Agency: NEI NIH HHS, United States
    Id: EY016145
  • Agency: NEI NIH HHS, United States
    Id: R01 EY011721
  • Agency: NEI NIH HHS, United States
    Id: R29 EY011721
  • Agency: NCI NIH HHS, United States
    Id: R01 CA090691
  • Agency: NCI NIH HHS, United States
    Id: CA90691
  • Agency: NEI NIH HHS, United States
    Id: R01 EY016145
  • Agency: Howard Hughes Medical Institute, United States
  • Agency: NEI NIH HHS, United States
    Id: EY016486

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


C57BL/6J (tool)

RRID:IMSR_JAX:000664

Mus musculus with name C57BL/6J from IMSR.

View all literature mentions

DBA/2J (tool)

RRID:IMSR_JAX:000671

Mus musculus with name DBA/2J from IMSR.

View all literature mentions